PROCEPT BioRobotics Corp. to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022

Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced it will report its financial results for the fourth quarter and full year 2021 on March 8, 2022, before market open. A conference call will be held at 5:00 a.m. PT / 8:00 a.m. ET. Investors can listen by calling (800) 306-0005 domestically or (209) 905-5968 internationally. The AquaBeam Robotic System, designed for minimally-invasive urologic surgery, targets benign prostatic hyperplasia, affecting around 40 million men in the U.S. There is a strong clinical evidence base supporting Aquablation therapy.

Positive

• Conference call scheduled for March 8, 2022, presenting Q4 and annual results.
• AquaBeam Robotic System is aimed at treating Benign Prostatic Hyperplasia, a condition affecting 40 million men.
• Significant clinical evidence with nine studies and over 100 peer-reviewed publications supporting Aquablation therapy.

Negative

• None.

REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PROCEPT^® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report finical results for the fourth quarter and full year 2021 before market open on Tuesday, March 8, 2022. The company’s management will webcast a corresponding conference call beginning at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (800) 306-0005 for domestic callers or (209) 905-5968 for international callers, using conference ID: 2515587. Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com.

An archived recording will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Gilmartin Group
Matt Bacso, CFA
Matt.bacso@gilmartinir.com

FAQ

When will PROCEPT BioRobotics report its Q4 and full year 2021 financial results?

PROCEPT BioRobotics will report its financial results on March 8, 2022.

What is the AquaBeam Robotic System used for?

The AquaBeam Robotic System is designed for minimally-invasive surgery aimed at treating benign prostatic hyperplasia (BPH).

How many men in the U.S. are affected by BPH?

Approximately 40 million men in the United States are affected by benign prostatic hyperplasia (BPH).

What evidence supports the effectiveness of Aquablation therapy?

There are nine clinical studies and over 100 peer-reviewed publications supporting the benefits of Aquablation therapy.